A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a human monoclonal antibody, REGN2222, for the prevention of medically attended RSV infection in12/23/2015 - 06/17/2017 (PI)
Regeneron Pharmaceuticals, Inc.
A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents10/01/2003 - 12/31/2016 (PI)
Merck & Company, Inc.
A phase II, observer-blind, randomized, controlled, multi-centre study to evaluate the immunogenicity and safety of GSK Biologicals quadrivalent influenza vaccine candidate10/23/2013 - 09/30/2016 (PI)
GlaxoSmithKline LLC
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II08/04/2014 - 08/03/2016 (PI)
Merck, Sharp & Dohme LLC
A phase IIIb, open, randomized, controlled, multicenter study to assess the co-administration of Rotarix (GlaxoSmithKline Biologicals') with Hib-MenCY-TT07/01/2013 - 06/30/2016 (PI)
GlaxoSmithKline LLC
A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762)08/15/2014 - 07/31/2015 (PI)
GlaxoSmithKline LLC
A phase IIIA, blinded randomized controlled multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR Vaccine (209762) compared to Merck's10/01/2012 - 06/30/2015 (PI)
GlaxoSmithKline LLC
Immunogenicity and Safety of GSK Biologicals' Combined Measles-Mumps-Rubella Vaccine in Subjects Four to Six Years of Age07/01/2012 - 06/30/2015 (PI)
GlaxoSmithKline LLC
A Phase III Double blind, randomized, multicenter, controlled study to evaluate the safety, tolerability and immunogenicity of measles, mumps, rubella, varicella (MMRV) vaccine made with an alternativ07/01/2012 - 06/30/2015 (PI)
Merck & Company, Inc.
A Phase 3, Open-label, Randomized, Parallel-group, Multi-center Study to Evaluate the Safety and Immunogenecity of Novartis Meningococcal ACWY Conugate Vaccine when Administered with Routine Infant Va11/19/2008 - 11/18/2013 (PI)
Novartis Vaccines and Diagnostics, Inc.
Showing 10 of 45 results.
Show All Results
A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity and Viral Shedding of MEDI-559, A Live Attenuated Intranasal Vaccine Against11/13/2009 - 06/30/2013 (PI)
MedImmune, Inc.
A Phase III, randomized, multicenter study, doubleblind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals' Haemophilus influenzae type b (Hib) conjugate vaccine and11/13/2009 - 06/30/2013 (PI)
GlaxoSmithKline LLC
A Phase II, Open, Controlled, Multicenter Study to Evaluate the Long-term Antibody Persistence at 1, 3, and 5 Years after the Administration of a Booster Dose of Hib-MenCY-TT Vaccine Compared to08/01/2006 - 01/31/2013 (PI)
GlaxoSmithKline LLC
A phase II, randomized, observer blind, controlled, multicenter study to assess immunogenicity and antibody persistence following vaccination with GSK's candidate combined measles, mumps, and ru01/13/2009 - 10/31/2012 (PI)
GlaxoSmithKline LLC
A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccination to Healthy In11/19/2008 - 06/30/2012 (PI)
Novartis Pharmaceuticals Corporation
A Phase III, Open, Randomized, Controlled, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline's Biologicals (GSK Biologicals)02/15/2008 - 06/30/2012 (PI)
GlaxoSmithKline LLC
A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered with Routine Infant Vaccinations03/09/2007 - 06/30/2012 (PI)
Novartis Vaccines and Diagnostics, Inc.
A Phase III , Randomized, Multinational Study, Double-Blinded for the Immunogenecity and Consistency Evaluation for 3 Hib-MenCY-TT Vaccine Lots and Single-Blinded and Controlled for the Evaluatio12/27/2005 - 06/30/2012 (PI)
GlaxoSmithKline LLC
A Randomized, Double-Blind Trial to Assess The Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine In Children 6-59 Months of Age09/01/2004 - 02/29/2012 (PI)
MedImmune, Inc.
Safety Study of Menactra (Menigococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered with Other Pediatric Vaccines to Healthy Toddlers12/01/2007 - 12/31/2009 (PI)
Sanofi-Pasteur, SA
A Phase IV, Randomized, Double-Blinded Study to Compare the Immune Reactivity of the Lipid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease09/30/2005 - 09/29/2007 (PI)
MedImmune, Inc.
Safety and Efficacy of Pentavalent (G1, G2, G3, G4, and P1) Human-Bovine Reassortant Rotavirus Vaccine in Health Infants08/25/2003 - 09/30/2006 (PI)
Merck & Company, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of Valtrex 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Inf01/25/2005 - 02/26/2006 (PI)
GlaxoSmithKline, Inc.
A Comparison of the Safety and Tolerability of a Second Dose of MMRII Manufactured with Recombinant Human Albumin (rHA) to MMRII Manufactured with Pooled-Donor Human Serum Albumin (HSA) in Healthy Children01/01/2002 - 07/31/2005 (PI)
Merck & Company, Inc.
A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard Care Therapy in the Treatment of Children with Community Acquired Pneumonia in the Hospitalized or Outpatient Setting01/28/2003 - 01/28/2005 (PI)
Johnson & Johnson
A Study To Determine Immunogenicity and Tolerability of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Like Particle (VLP) Vaccine in Pre-Adolescents and Adolescents and To Determine End-Expiry Specifications of the Protocol01/01/2003 - 12/31/2004 (PI)
Merck & Company, Inc.
A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella and Varicella Combination Vaccine Proquad (Refrigerated) versus Proquad (frozen) in Healthy Children11/11/2002 - 11/10/2004 (PI)
Merck & Company, Inc.
A Multicenter, Long Term, Active-Surveillance Study of Musculoskeletal Disorders that Occur after Initiating a Course of Levofloxacin of Non-Fluroquinolone Therapy for Acute Infectious Diseases in Children who Were Enrolled in Phase 3 Clinical Trials Invo01/31/2003 - 06/01/2004 (PI)
Johnson & Johnson
A Phase III, Observer Blinded, Multicenter, Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals dTpa Candidate Vaccine as Compared to a US-Licensed TD Vaccine when Geven as a Booster Dose to Healthy 02/12/2003 - 02/11/2004 (PI)
GlaxoSmithKline, Inc.
A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children with Community Acquired Pneumonia in the Hospitalization or Outpatient Setting01/01/2003 - 01/01/2004 (PI)
Johnson & Johnson
Open-Label Multicenter Multiple Dose Phase III Study of the Population Pharmacokinetics of IV Synecid 7.5 mg/kg q8h in &5 Pediatric Patients11/01/2001 - 10/31/2003 (Co-PI)
PI:
Mark H. Mirochnick, MDAventis Pharmaceuticals Inc
Surveillance of Streptococcus Pneumoniae Serotypes Causing Acute Otorrhea in Children with Tympanostomy Tubes and colonizing Healthy Infants09/21/2000 - 09/30/2003 (PI)
Wyeth-Ayerst Pharmaceuticals Inc
A Phase III... Study of the Immunogenicity and Safety of Three Doses of GSK Biologicals’ Thiomersal-Free Hepatitis B Vaccine (10 mcg/0.5ml) Compared to the US-licensed GSK Biologicals’ Preservative-Free Hepatitis B Vaccine (Engerix-B, 10mcg/0.5 Ml) When A03/01/2002 - 03/01/2003 (PI)
GlaxoSmithKline, Inc.
A Randomized Partially Blinded Placebo Controlled Trial to Investigate Immune Response Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A&B, Live Cold Adapted (CAIV-T) in Healthy Children Aged 6 to less than 36 Months.09/01/2001 - 08/31/2002 (PI)
Wyeth-Ayerst Pharmaceuticals Inc
Administration of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (MMRV) to Healthy Children at 4 to 6 Years of Age.09/01/2001 - 08/31/2002 (PI)
Merck & Company, Inc.
A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRII (R) ) and Varicella (VARIVAX (R) Vaccines Admini06/08/2001 - 08/31/2002 (PI)
Aviron
Comparison of the Safety, Tolerability, and Immunogenicity of P32 Process Upgrade Varicella Vaccine (PUVV) to P31 PUVV When Each is Administered Concomitantly with MMRII to Subjects 12-23 Months of Age.05/22/2000 - 05/31/2002 (PI)
Merck & Company, Inc.
An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Frozen MMRV Given Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines in Healthy Children 12 to 15 Months of Age04/01/2001 - 03/31/2002 (PI)
Merck & Company, Inc.
Phase II, Double Blind Randomized, Placebo Controlled Study of Two Doses of SKB Biologicals Live Attenuated Human Rotavirus (HRV) Vaccine at Different Virus Concentrations in Health Infants Following a 0,2 Month Schedule and Previously Uninfected with Hum12/30/2000 - 02/28/2002 (PI)
SmithKline Beecham
Phase III, Observer Blinded, Randomized, Multicenter, Comparative Clinical Study of the Reactogenicity, Safety and Immunogenicity of a Single Booster Dose of SB Biologicals Candidate dTpa Vaccine and Lederles US Licensed Td Vaccine in Healthy Younger Adol03/01/2000 - 02/28/2002 (PI)
SmithKline Beecham
An Open Label, Multicenter Non Comparative Study of Gatifloxacin in the Treatment of Recurrent Otitis Media in Children03/10/2000 - 12/31/2001 (PI)
Bristol-Myers Squibb
A Study of MMRII at Mumps Expiry Potency in Healthy Children 12-18 months of Age12/08/1999 - 12/31/2001 (PI)
Merck & Company, Inc.
A Phase III, Blinded, Randomized Multicenter U.S. Study Evaluating the Clinical Consistency of Three Production Lots of SmithKline Beecham Biologicals’ MMR Vaccine (PRIOrix) and Comparability of PRIOrix with Merck’s M-M-R II Vaccine, Administered to Healt06/19/1998 - 11/30/2001 (PI)
SmithKline Beecham
Comparison of the Safety, Tolerability, and Immunogenicity of Three Consistency Lots of Frozen Measles, Mumps, Rubella and Varicella Vaccine (MMRV) in Healthy Children05/10/2000 - 06/30/2001 (PI)
Merck & Company, Inc.
A Dose Selection Study in Healthy Children Comparing Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to M-M-RII Given Concomitantly with Process Upgrade Varicella Vaccine (PUVV) in Separate Injections04/19/1999 - 04/18/2001 (PI)
Merck & Company, Inc.
Assessing Rates of Fever and Other Adverse Events in Children after US Influenza Vaccines Using Text09/19/2014 - 09/18/2016 (PI)
CDC
Clinical Immunization Safety Assessment Safety (CISA) Center09/29/2012 - 09/28/2013 (PI)
CDC
A double-blind, randomized controlled phase III study01/12/2004 - 03/31/2013 (PI)
St. Louis University NIH
Vaccine Safety - CISA09/01/2002 - 09/29/2012 (PI)
America's Health Insurance Plans CDC
Vaccine Safety - CISA: Phase I H1N1 funding07/01/2010 - 06/30/2011 (PI)
America's Health Insurance Plans CDC
Clinical Immunization Safety A09/30/2001 - 09/29/2004 (PI)
CDC